follicular lymphoma on the skin - Health Topics
ascopubs.org: Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up PURPOSE: Unlike nodal follicular lymphoma (NFL), Primary cutaneous follicular lymphomas (PCFLs) rarely express Bcl-2 ... Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features The American Journal of Managed Care: Sequencing Anti-CD19 Therapies in Follicular Lymphoma Follicular Lymphoma: Symptoms, Causes, Diagnosis and Treatment: By Shreoshree Chakrabarty Follicular Lymphoma is a common type of non-Hodgkin lymphoma that develops in the lymphatic system, affecting ... The American Journal of Managed Care: Challenges to NGS Testing for Follicular Lymphoma in the Community Setting While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent.
Understanding the Context
There are disparities in the ... Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a malignancy where the first-generation drug ibrutinib (Imbruvica) failed. "When ... SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to a ...
Image Gallery
Key Insights
Cure Today: FDA Green Lights 'One-Minute' Injection for R/R Follicular Lymphoma Treatment Lunsumio VELO, a subcutaneous CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two systemic therapies. The GO29781 study reported a 75% objective response ... Cure Today: FDA to Speed Up Epkinly Development for Relapsed/Refractory Follicular Lymphoma The Food and Drug Administration granted a Breakthrough Therapy Designation to Epkinly to treat patients with relapsed or refractory follicular lymphoma. The Food and Drug Administration (FDA) granted ...